by Elena Iemma | Mar 29, 2024 | News
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ — Read the publication. In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk –...
by Elena Iemma | Mar 5, 2024 | Events
June 13 & 14, 2024 9:00am – 5:00pm (with receptions to follow!) 350 Eddy St. Providence, RI 02903 👉Click here to register The Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop will take place on June 13 and 14th at the South...
by Elena Iemma | May 17, 2023 | News
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...
by Elena Iemma | May 16, 2023 | News
EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere. 1998 EpiVax Founded by Dr....
by Elena Iemma | Sep 12, 2022 | News
PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk...
